Mizuho Upgrades Waters on Improving Pharma Picture

May 21, 2012

|

NEW YORK (GenomeWeb News) – Mizuho Securities today upgraded Waters' stock to Buy from Neutral, citing the firm's exposure to the pharma industry, its presence in emerging markets, and its "strong" product cycle.

Mizuho also increased the price target on Waters' stock to $92 from $84. The investment firm lowered full-year 2012 revenue estimates to $1.89 billion from $1.91 billion, while maintaining an EPS estimate of $5.10.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

Main menu